Macrogenics Inc financial data

Symbol
MGNX on Nasdaq
Industry
Pharmaceutical Preparations
Location
9704 Medical Center Drive, Rockville, Maryland
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 408 % -15.4%
Quick Ratio 2.1 % -26%
Debt-to-equity 113 % +6.54%
Return On Equity -107 % -2057%
Return On Assets -50.2 % -1993%
Operating Margin -480 % -659%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 62.7M shares +1.25%
Common Stock, Shares, Outstanding 62.7M shares +1.26%
Entity Public Float 323M USD +77.9%
Common Stock, Value, Issued 627K USD +1.29%
Weighted Average Number of Shares Outstanding, Basic 62.7M shares +1.27%
Weighted Average Number of Shares Outstanding, Diluted 62.7M shares +0.65%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 41M USD -73.1%
Research and Development Expense 175M USD -4.21%
General and Administrative Expense 54.1M USD -3.81%
Costs and Expenses 238M USD -4.43%
Operating Income (Loss) -197M USD -104%
Net Income (Loss) Attributable to Parent -136M USD -1931%
Earnings Per Share, Basic -2.2 USD/shares -1933%
Earnings Per Share, Diluted -2.19 USD/shares -2091%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 83.9M USD -22.8%
Accounts Receivable, after Allowance for Credit Loss, Current 6.19M USD -3.42%
Inventory, Net 1.12M USD -22.7%
Assets, Current 157M USD -38.4%
Property, Plant and Equipment, Net 20.4M USD -15.4%
Operating Lease, Right-of-Use Asset 22.6M USD -11.3%
Other Assets, Noncurrent 1.19M USD -14.4%
Assets 201M USD -34.2%
Accounts Payable, Current 5.24M USD +38%
Accrued Liabilities, Current 24.4M USD -11.2%
Contract with Customer, Liability, Current 23.8M USD +146%
Liabilities, Current 57.9M USD +28.2%
Contract with Customer, Liability, Noncurrent 55.5M USD -5.19%
Operating Lease, Liability, Noncurrent 29.7M USD -1.68%
Other Liabilities, Noncurrent 258K USD 0%
Liabilities 143M USD +6.87%
Retained Earnings (Accumulated Deficit) -1.21B USD -12.7%
Stockholders' Equity Attributable to Parent 57.8M USD -66.3%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 57.8M USD -66.3%
Liabilities and Equity 201M USD -34.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -45.6M USD -256%
Net Cash Provided by (Used in) Financing Activities 248K USD -99.8%
Net Cash Provided by (Used in) Investing Activities 24.8M USD -11.7%
Common Stock, Shares Authorized 125M shares 0%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -20.6M USD -118%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 83.9M USD -22.8%
Deferred Tax Assets, Valuation Allowance 365M USD -1.95%
Deferred Tax Assets, Gross 373M USD -2.07%
Operating Lease, Liability 34M USD -2.48%
Payments to Acquire Property, Plant, and Equipment 1.46M USD +306%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -136M USD -1870%
Lessee, Operating Lease, Liability, to be Paid 70.3M USD -6.64%
Property, Plant and Equipment, Gross 110M USD -3.01%
Operating Lease, Liability, Current 4.41M USD +5.89%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.08M USD +27%
Lessee, Operating Lease, Liability, to be Paid, Year One 4M USD -19.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 36.3M USD -10.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.21M USD -17.2%
Unrecognized Tax Benefits 7.82M USD +6.03%
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.93M USD +17.1%
Depreciation, Depletion and Amortization 1.84M USD -38.3%
Deferred Tax Assets, Net of Valuation Allowance 8.4M USD -7.09%
Share-based Payment Arrangement, Expense 21.4M USD +11.9%
Interest Expense 1.14M USD -99.2%